Shares in Biogen (NSDQ:BIIB) rose today after the biopharmaceutical company met expectations on Wall Street with its second quarter results.
The Cambridge, Mass.-based company posted profits of $863 million, or $4.07 per share, on sales of $3.1 billion for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of 6% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.